One-year experience with intravenous treprostinil for pulmonary arterial hypertension

Journal of Heart and Lung Transplantation

Volumn 32, Issue 9, 2013, Pages 889-896

  Benza, Raymond L ^a   Tapson, Victor F ^b   Gomberg Maitland, Mardi ^c   Poms, Abigail ^b   Barst, Robyn J ^d   McLaughlin, Vallerie V ^e  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d Barst Consulting   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

prostacyclin; pulmonary arterial hypertension; treprostinil

Indexed keywords

BOSENTAN; PROSTACYCLIN; SILDENAFIL; TREPROSTINIL;

ADOLESCENT; ADULT; AGED; ARM PAIN; ARTICLE; BACKACHE; CATHETER INFECTION; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; DIARRHEA; DRUG WITHDRAWAL; EXERCISE; FEMALE; FLUSHING; FOLLOW UP; HEADACHE; HEART ARREST; HEMODYNAMICS; HUMAN; JAW PAIN; KIDNEY FAILURE; LEG PAIN; LOOSE FECES; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SCHOOL CHILD; SIDE EFFECT; SUBDURAL HEMATOMA; TREADMILL EXERCISE; WALKING; WORLD HEALTH ORGANIZATION;

PROSTACYCLIN; PULMONARY ARTERIAL HYPERTENSION; TREPROSTINIL;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHILD; ENDPOINT DETERMINATION; EPOPROSTENOL; EXERCISE TOLERANCE; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; TREATMENT OUTCOME; WALKING; YOUNG ADULT;

EID: 84881593251     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2013.06.008     Document Type: Article

References (32)

1. R.J. Barst, L.J. Rubin, and W.A. Long A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group N Engl J Med 334 1996 296 301
2. N. Galie, H.A. Ghofrani, and A. Torbicki Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 2005 2148 2157
3. H. Olschewski, G. Simonneau, and N. Galie Inhaled iloprost for severe pulmonary hypertension N Engl J Med 347 2002 322 329
4. L.J. Rubin, D.B. Badesch, and R.J. Barst Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 2002 896 903
5. G. Simonneau, R.J. Barst, and N. Galie Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial Am J Respir Crit Care Med 165 2002 800 804
6. R.L. Benza, D.P. Miller, and M. Gomberg-Maitland Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) Circulation 122 2010 164 172
7. M. Humbert [A critical analysis of survival in idiopathic pulmonary arterial hypertension] Presse Med 39 Suppl 1 2010 1S41 45
8. R.L. Benza, M. Gomberg-Maitland, and D.P. Miller The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension Chest 141 2012 354 362
9. M. Delcroix, K. Spaas, and R. Quarck Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy Eur Respir Rev 18 2009 253 259
10. H. Farber, D. Miller, F. Beery, and M. McGoon Use of parenteral prostanoids at time of death in patients with pulmonary arterial hypertension enrolled in REVEAL Chest 140 2011 903A
11. ®) administered by the intravenous and subcutaneous route to normal volunteers J Cardiovasc Pharmacol 44 2004 209 214
12. C.S. McSwain, R. Benza, and S. Shapiro Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion J Clin Pharmacol 48 2008 19 25
13. V.V. McLaughlin, S.P. Gaine, and R.J. Barst Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension J Cardiovasc Pharmacol 41 2003 293 299
14. D.B. Badesch, V.F. Tapson, and M.D. McGoon Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease A randomized, controlled trial. Ann Intern Med 132 2000 425 434
15. V.V. McLaughlin, A. Shillington, and S. Rich Survival in primary pulmonary hypertension. The impact of epoprostenol therapy Circulation 106 2002 1477 1482
16. E.B. Rosenzweig, D. Kerstein, and R.J. Barst Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects Circulation 99 1999 1858 1865
17. O. Sitbon, M. Humbert, and H. Nunes Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 2002 780 788
18. K. Laliberte, S. Jerat, K. Tenneson, M. Wade, and D. Zaccardelli Continuous low volume delivery of intravenous treprostinil via a central venous catheter with a miniature pump in a conscious dog model J Vasc Access 6 2005 177 181
19. K.R. Phares, W.E. Weiser, S.P. Miller, M.A. Myers, and M. Wade Stability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluents Am J Health-Syst Pharm 60 2003 916 922
20. O. Sitbon, A. Manes, and X. Jais Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension J Cardiovasc Pharmacol 49 2007 1 5
21. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. J Am Coll Cardiol 2009;53:1573-619.
22. V.F. Tapson, M. Gomberg-Maitland, and V.V. McLaughlin Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial Chest 129 2006 683 688
23. M. Gomberg-Maitland, V.F. Tapson, and R.L. Benza Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension Am J Respir Crit Care Med 172 2005 1586 1589
24. A.C. Widlitz, S. McDevitt, G.R. Ward, and A. Krichman Practical aspects of continuous intravenous treprostinil therapy Crit Care Nurse 27 2007 41 50
25. I. Lang, M. Gopmez-Sanchez, and M. Kneussi Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension Chest 129 2006 1636 1643
26. R. Sadushi-Koliçi, N. Skoro-Sajer, and D. Zimmer Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension J Heart Lung Transplant 31 2012 735 743
27. R.J. Barst, N. Galie, and R. Naeije Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Eur Respir J 28 2006 1195 1203
28. O.A. Minai, and M.M. Budev Treating pulmonary arterial hypertension: cautious hope in a deadly disease Cleve Clin J Med 74 2007 789 806
29. Centers for Disease Control and Prevention (CDC) Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension - seven sites, United States, 2003-2006 MMWR Morb Mortal Wkly Rep 56 2007 170 172
30. D.D. Ivy, M. Calderbank, and B.D. Wagner Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension Infect Control Hosp Epidemiol 30 2009 823 829
31. J.D. Rich, C. Glassner, and M. Wade The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension Chest 141 2012 36 42
32. D. Zaccardelli, K. Phares, R. Jeffs, A. Doran, and M. Wade Stability and antimicrobial effectiveness of treprostinil sodium in sterile diluent for Flolan Int J Clin Pract 64 2010 885 891